GCG and Parkinson disease: Interestingly, the GLP-1 RA exenatide, in its extended-release formulation, has been successfully employed to alleviate the motor symptoms of PD patients [73], a condition characterized by a deficit in dopaminergic neurotransmission, a critical axis of the reward system.